Azithromycin in Atopic Dermatitis

Sponsor
Cairo University
Study ID
NCT07713186
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
3 Years - 12 Years
Healthy Volunteers
Not accepted

Interventions

  • Betamethasone or tacrolimus ointments — DRUG
    Topical treatment will be applied, Betamethasone or tacrolimus ointments
  • Azithromycin — DRUG
    Azithromycin will be combined with topical treatment

Study Details

The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis

Key Dates

First listed
Jul 20, 2026
Start date
Aug 1, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Topical corticosteroids and tacrolimus
    Atopic dermatitis patients on topical betamethasone and tacrolimus ointments
  • Experimental: Azithromycin
    Atopic dermatitis treated with azithromycin besides topical betamethasone and tacrolimus ointments

Primary Outcome Measure

Improvement in Eczema Area and Severity Index (EASI) [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies